Navigation Links
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
Date:7/29/2008

BRIDION allows anesthesiologists to rapidly reverse both moderate and deep

levels of muscle relaxation First product approval from the Schering-Plough combination with Organon

BioSciences

KENILWORTH, N.J., July 29 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission (EC) has approved BRIDION(R) (sugammadex) injection, the first and only selective relaxant binding agent (SRBA) and the first major pharmaceutical advance in the field of anesthesia in two decades. BRIDION is indicated for routine reversal of the commonly used muscle relaxants rocuronium or vecuronium and for immediate reversal of rocuronium in adults, and for routine reversal following rocuronium in children and adolescents (2-17 years of age). Rocuronium and vecuronium are given as part of general anesthesia to relax a patient's muscles during surgery, and are marketed in Europe under the trade names ESMERON(R) and NORCURON(R), respectively.

BRIDION works in an entirely novel way by encapsulating the muscle relaxant molecule and rendering it inactive. It was specifically designed to reverse within minutes both moderate and deep muscle relaxation induced by rocuronium or vecuronium during general anesthesia. As a result, BRIDION can give anesthesiologists greater control in managing the depth of muscle relaxation through to the end of a surgical procedure. This may help improve surgical conditions in the millions of procedures where these agents are used.

"This approval of BRIDION represents the first advance in two decades for anesthesiologists and their patients, and has the potential to transform the practice of anesthesia," said Thomas P
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
8. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
9. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
10. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BERGEN, Norway , September 23, 2014 /PRNewswire/ ... "Company"), an oncology biopharmaceutical company, today announces it ... million) Seeding Drug Discovery Award from the UK,s ... against BGB002, its proprietary, novel cancer target. ... are to identify and fund especially promising, innovative ...
(Date:9/23/2014)... , Sept. 23, 2014  As physicians ... to digital communication channels to learn about new ... finding – from a new report by global ... – shows that communicating via a customized mix ... provides the best opportunity to engage with physicians. ...
(Date:9/23/2014)... , Sept. 23, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... additions to its Scientific Advisory Board.  The new members ... Davies , PhD. Dr. Acker is a ...
Breaking Medicine Technology:BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7
... Harco Metal Products (Harco), an industry leader in tube fabrication, systems ... manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products for health ... cost associated with staff injuries caused by physically lifting and moving ...
... 23 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... 26, 2010 , at 8:00 a.m. Eastern Time ( 5:00 ... , , ... live webcast of the presentation on the company,s website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar ...
Cached Medicine Technology:Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib 2
(Date:9/23/2014)... a driving force behind many chronic diseases, especially ... inflammation caused by conditions such as viral hepatitis ... options. Now, scientists at Virginia Commonwealth University Massey ... in preclinical studies that blocking the expression of ... halts the development and progression of liver cancer ...
(Date:9/23/2014)... Wellesley, Mass., September 23, 2014 – BCC Research ( ... Joint Reconstruction and Replacement: Materials, Technologies, and Global Markets ... is expected to increase to nearly $16.2 billion by ... 4.2% from 2013 through 2018. The U.S. occupies the ... CAGR of 5.1%. , Revision and partial joint replacement ...
(Date:9/23/2014)... eCaring, a leading health care quality ... contract to provide its unique Web-based home health care ... New York City’s largest not-for-profit health plans. Elderplan, an ... to help enhance the care of its Medicare, Medicaid ... Elderplan has been at the forefront of offering New ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 ... revenue for the Fruit and Vegetable Markets ... consumption and fruit prices benefited operators over the ... industry follow unique preference and demographic trends, including ... US population. While per capita fruit and vegetable ...
(Date:9/23/2014)... the results of their cancer research at ESMO ... Joint Symposium: ESMO-ASCO: The Evolution of the ... AM - 12:30 PM, Room: Granada, Abstract 121IN: ... new forms of cancer clinical research? The example ... Paper session: Melanoma and other skin tumors , ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 3Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:EORTC presentations at ESMO 2014 Congress 2Health News:EORTC presentations at ESMO 2014 Congress 3
... new study has established the wholesomeness of whole wheat ... breast cancer risk in the offspring.// ,Dr ... her colleagues examined the benefits of dietary changes on ... health. These results could well mimic the occurrence in ...
... health care for patients that was released by the ... countries, except the U.S. ,In the survey ... was found that Canada lagged in several aspects including ... doctors availability after hours, multi-discipline teams for treatment of ...
... to arouse strong feelings either way has been brought up ... the proposal suggests mercy killing of// new borns who are ... Gynaecology put forth this recommendation as the solution to the ... are being kept alive because of the advanced technology ...
... 7 and the theme selected is Cancer and Women. ... on that day// to promote awareness and motivate people ... ,"Run 4 Cancer" will be flagged off by SSP ... Allahabad Division RN Tripathi will preside over a lecture ...
... a biotechnology firm based in Seattle has called off further ... year following the untimely deaths// of few of the patients ... efficacy of the cancer drug Xyotax. ,The CEO of ... the volunteer s who were cancer patients do not seem ...
... raising the retirement age for civil servants from 60 to ... soaring pension bill//. ,Moreover, improving health standards and ... retiring are being cited among the reasons for the move. ... Reforms (NCGR) told The News International that the reform body ...
Cached Medicine News:Health News:Consider Euthanasia For Severely Disabled Babies, College Tells Doctors 2Health News:Awareness about Women's Cancers- A National Concern 2Health News:Multiple deaths forces cancer trial to be called off 2Health News:Pakistan civil servants may retire at 62 2
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Inquire...
... aerosol contamination, which causes ... PCR. Hydrophobic, nonwicking and ... can pass through these ... contrast to tips with ...
... offer a safe alternative to using positive ... applications such as PCR(a), pipetting radioactive materials ... are excellent for tissue culture, gel loading, ... prevent aerosol contaminants and liquids from reaching ...
Medicine Products: